MGMT and glioblastoma: The predictive value of MGMT methylation status as a biomarker was notably corroborated by the Stupp trial, which demonstrated a substantial survival advantage when temozolomide was administered in conjunction with standard radiotherapy for patients with MGMT-methylated glioblastoma, as opposed to those with an unmethylated MGMT gene.